<DOC>
	<DOCNO>NCT00668330</DOCNO>
	<brief_summary>The primary aim present study investigate prevalence low bone mineral density ( BMD ) vertebral fracture , determine standardized assessment , elucidate role bone quality , include micro-architecture , bone remodeling , bone turnover , mineralization inflammation bone density prevalent vertebral fracture large population systemic lupus erythematosus ( SLE ) patient . The secondary aim study evaluate follow parameter woman steroid induced OP ( SIOP ) 1 year treatment use : 1 . The change BMD use dual energy X-ray absorptiometry ( DXA ) 2 . Bone mineralization architecture in-vivo use newly available high-resolution human micro-computed tomography ( ExtremCT ) , provide u new insight degree distribution mineralization affect long-term oral Ibandronate treatment . 3 . Changes perfusion marrow edema treatment Ibandronate use dynamic Magnetic Resonance Imaging ( MRI ) patient SIOP . 4 . The investigator prospectively evaluate correlation change brachial arterial endothelial function lumbar spine BMD female lupus patient period 1 year .</brief_summary>
	<brief_title>Steroid Induced Osteoporosis Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>In first part study , 150 consecutive patient diagnosis SLE include study . All patient fulfil American College Rheumatology ( ACR ) revise criterion classification SLE provide write informed consent . Data collect time study inclusion age , disease duration , race , menstrual status , age menopause , period amenorrhea , family history osteoporosis , ultraviolet ( UV ) light intolerance , sunshine avoidance , use sunscreen previous year , calculate mean daily dietary calcium intake last 3 month , history ( non ) vertebral fracture age 25 year , comorbidity , alcohol tobacco intake , exercise status.Body weight , height , body mass index ( BMI ) assess . Disease activity score use Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI ) 54 . Accumulated organ damage assess SLICC/ ACR damage index ( DI ) 55 . A modified DI score derive DI score exclude osteoporotic fracture damage item.BMD measurement hip ( total hip femoral neck ) lumbar spine ( L1-4 ; anteroposterior view ) well lateral radiograph thoracic lumbar spine ( T5-L4 ) perform . The prevalence low BMD vertebral fracture assess . In second part study , 40 female SLE patient steroid induce osteopenia enrol 12-month , randomize , parallel-group , control study . Patients receive either oral Ibandronate 150 mg monthly plus daily alfacalcidol ( 0.001 mg ) placebo ibandronate monthly plus daily alfacalcidol ( 0.001mg ) .In addition , intake dietary calcium estimate questionnaire screen visit . All patient receive daily calcium supplement ( 500 mg ) . Primary outcome improvement bone mineral density measure DEXA . Secondary outcome include : 1 . Evaluation change bone mineralization architecture measure Xtreme CT. 2 . Evaluation change perfusion marrow edema use MRI . 3 . Anti-proliferative anti-inflammatory action alfacalcidol use serum level interleukin-6 ( IL-6 ) , transform growth factor-beta-1 , angiotensin-II , well urinary level TGF monocyte chemoattractant protein-1 ( MCP-1 ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Part I Fulfilled ACR revise criterion classification SLE Provided write informed consent participation Part II Have low BMD ( T socre &lt; 1 S.D . lumbar spine ( L1L4 ) total hip ) induce longterm administration highdose corticosteroid . Had receive chronic uninterrupted corticosteroid therapy least 1 year receive corticosteroid dose least 5 mg/day . Hypocalcaemia , hypercalcaemia , Hypercalciuria , creatinine clearance le 30 ml per minute . A history nephrolithiasis previous five year . A history recent major gastrointestinal ( GI ) tract disease ( e.g . oesophagitis ) . Had presence primary hyperparathyroidism , hyperthyroidism , hypothyroidism year study begin . Had experience previous adverse reaction bisphosphonate therapy ( alendronate , fosamax , ibandronate ) . With uncontrolled active recurrent peptic ulcer disease . Receiving therapy ( within last 6 month ) know affect bone metabolism , include : hormonereplacement agent , calcitonin , active vitamin D3 analogue , thiazide diuretic , treatment bisphosphonates , fluoride treatment within last 12 mon total duration 2 year ; contraindication calcium vitamin D therapy . Pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bone mineral density</keyword>
	<keyword>ibandronate</keyword>
	<keyword>alfacalcidol</keyword>
</DOC>